Full Text Journal Articles from
Abstract 31593976


Find full text journal articles

Adoptive cell therapies for posttransplant infections.

PMID: 31593976 (view PubMed database entry)
DOI: 10.1097/cco.0000000000000580 (read at publisher's website )

Gaurav Sutrave, David J Gottlieb,

Department of Haematology, Westmead Hospital.

PURPOSE OF REVIEW:Viral and fungal infections cause significant morbidity and mortality following hematopoietic stem-cell transplantation (HSCT), primarily due to the prolonged and complex immunodeficient state that results from conditioning chemo-radiotherapy and subsequent prophylaxis of graft vs. host disease. Although currently available antimicrobial pharmacotherapies have demonstrated short-term efficacy, their toxicities often preclude long-term use, and cessation if frequently associated with recurrent infection. Adoptive cell therapy (ACT) offers the potential to more rapidly reconstitute antimicrobial immune responses in the posttransplant setting. RECENT FINDINGS:Traditional approaches to manufacture of adoptive T-cell therapies are time consuming and limited to single pathogen specificity. Recent advances in the understanding of immunogenic epitopes, improved methods for pathogen-specific T-cell isolation and cultureware technologies is allowing for rapid generation of ACTs for clinical use. SUMMARY:The current review summarizes the potential infectious targets and manufacturing methodologies for ACTs and contrasts their clinical efficacy and safety to currently available pharmacotherapies for patients recovering after HSCT.

Curr Opin Oncol (Current opinion in oncology)
[2019, 31(6):574-590]

Cited: 0 times

AltMetric Statistics
Authors' Affiliation
Map for Author Affiliation


0.8134 s